Coherus BioSciences (CHRS) Upgraded at BidaskClub

Coherus BioSciences (NASDAQ:CHRS) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Tuesday, May 8th.

CHRS has been the subject of several other research reports. Maxim Group set a $18.00 price objective on shares of Coherus BioSciences and gave the company a “buy” rating in a research report on Thursday, May 3rd. ValuEngine upgraded shares of Coherus BioSciences from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Zacks Investment Research cut shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, Citigroup lifted their price target on shares of Coherus BioSciences from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, March 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. Coherus BioSciences currently has an average rating of “Buy” and an average price target of $30.11.

Coherus BioSciences traded down $0.05, reaching $15.90, during midday trading on Tuesday, Marketbeat Ratings reports. The stock had a trading volume of 4,958 shares, compared to its average volume of 735,687. The company has a current ratio of 4.06, a quick ratio of 4.06 and a debt-to-equity ratio of -33.10. Coherus BioSciences has a 1-year low of $16.30 and a 1-year high of $16.50. The firm has a market capitalization of $984.73 million, a PE ratio of -3.56 and a beta of 3.39.



Coherus BioSciences (NASDAQ:CHRS) last released its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.04). analysts anticipate that Coherus BioSciences will post -2.91 EPS for the current fiscal year.

In other Coherus BioSciences news, insider Dennis M. Lanfear sold 20,984 shares of Coherus BioSciences stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $16.26, for a total value of $341,199.84. Following the transaction, the insider now owns 92,619 shares of the company’s stock, valued at $1,505,984.94. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 26.28% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Swiss National Bank lifted its position in shares of Coherus BioSciences by 10.5% in the fourth quarter. Swiss National Bank now owns 57,700 shares of the biotechnology company’s stock worth $508,000 after purchasing an additional 5,500 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Coherus BioSciences by 2.7% in the first quarter. Wells Fargo & Company MN now owns 218,448 shares of the biotechnology company’s stock worth $2,413,000 after purchasing an additional 5,658 shares in the last quarter. Royal Bank of Canada lifted its position in shares of Coherus BioSciences by 26.2% in the first quarter. Royal Bank of Canada now owns 32,526 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 6,754 shares in the last quarter. Northern Trust Corp lifted its position in shares of Coherus BioSciences by 1.9% in the first quarter. Northern Trust Corp now owns 477,300 shares of the biotechnology company’s stock worth $5,274,000 after purchasing an additional 8,760 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. lifted its position in shares of Coherus BioSciences by 34.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 35,762 shares of the biotechnology company’s stock worth $314,000 after purchasing an additional 9,100 shares in the last quarter. 81.38% of the stock is currently owned by institutional investors and hedge funds.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.

Analyst Recommendations for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply